Login
Shattuck Labs, Inc. logo

Shattuck Labs, Inc.

shattucklabs.com

What Do They Do?

Develops monoclonal and bispecific antibodies that block an immune-cell receptor for people with inflammatory and immune-mediated diseases.

How Do They Make Money?

Licensees pay for rights to research, develop and commercialize product candidates; upfront fees are tied to transfer of the license, milestone payments to specified events, and royalties to related sales. Payments for research services come as the related work is done.

FY2025 revenue by product or service revenue
SegmentShareRevenue
Related party license revenue
Licensed

100%
Collaboration revenue:
0.0%

Who Are Their Customers?

Licensees obtain rights to Shattuck’s intellectual property; collaboration arrangements can also cover research, development and manufacturing services.

Do Revenues Turn Into Profits?

No. It lost $48.8M in FY2025.

Operating income, FY2025
−5151% of revenue
▲ +36% (Loss) vs FY2024 (−$80.6M, −1408%)
Net income, FY2025
−4881% of revenue
▲ +35% (Loss) vs FY2024 (−$75.4M, −1318%)
Free cash flow, FY2025
−3995% of revenue
▲ +34% (Loss) vs FY2024 (−$60.6M, −1059%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −100%
vs $1M in Q3 FY2025
Net income
▼ −151% (Loss)
vs −$10.1M in Q3 FY2025

Shrinking. Revenue fell 97% in 4 years, from $30M in FY2021 to $1M in FY2025, about 57% a year.

From fusion proteins to receptor-blocking antibodies The older report focused on dual-sided fusion proteins for cancer and immune therapies, including its ARC and GADLEN platforms. The latest report centers on monoclonal and bispecific antibodies that block a receptor for inflammatory and immune-mediated diseases.

Revenue over time
Related party license revenue Collaboration revenue:
$10M$5M$0

Who Do They Compete With?

Competes with Abbvie, Johnson & Johnson, Merck, Novartis, Pfizer, Roche/Genentech, Sanofi, Teva, Takeda, Hoffmann-La Roche, Spyre Therapeutics, Xencor, and Absci

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support